MPM Bioimpact LLC Has $12.43 Million Stake in Twist Bioscience Co. (NASDAQ:TWST)

MPM Bioimpact LLC cut its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 9.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 267,497 shares of the company's stock after selling 27,433 shares during the period. Twist Bioscience makes up approximately 1.8% of MPM Bioimpact LLC's holdings, making the stock its 26th largest holding. MPM Bioimpact LLC owned about 0.45% of Twist Bioscience worth $12,431,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TWST. Van ECK Associates Corp increased its stake in Twist Bioscience by 56.4% during the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares during the last quarter. Banque Transatlantique SA acquired a new position in shares of Twist Bioscience during the fourth quarter valued at $43,000. US Bancorp DE boosted its stake in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after buying an additional 601 shares in the last quarter. KBC Group NV boosted its stake in Twist Bioscience by 71.4% during the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after buying an additional 1,226 shares in the last quarter. Finally, Wealthfront Advisers LLC bought a new position in Twist Bioscience during the fourth quarter valued at about $209,000.

Twist Bioscience Stock Up 2.8%

Twist Bioscience stock traded up $0.83 during mid-day trading on Friday, hitting $30.93. The company's stock had a trading volume of 1,288,988 shares, compared to its average volume of 970,481. The company has a market cap of $1.85 billion, a PE ratio of -9.15 and a beta of 2.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a 52-week low of $28.46 and a 52-week high of $60.90. The firm's 50 day moving average is $37.82 and its 200 day moving average is $43.29.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The firm had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. On average, analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Robert W. Baird decreased their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. JPMorgan Chase & Co. decreased their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Guggenheim reiterated a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. Finally, The Goldman Sachs Group decreased their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $50.40.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 5,042 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $189,831.30. Following the transaction, the chief executive officer now directly owns 655,432 shares of the company's stock, valued at approximately $24,677,014.80. This trade represents a 0.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Patrick John Finn sold 2,800 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $105,420.00. Following the completion of the transaction, the chief operating officer now directly owns 262,660 shares in the company, valued at $9,889,149. The trade was a 1.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,991 shares of company stock valued at $742,654. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.